A Randomized, Double-Blind, Placebo-Controlled Trial Of TOL-463 Insert for Suppression Of Bacterial Vaginosis (BV) [SUBVert]
Latest Information Update: 23 Feb 2023
At a glance
- Drugs TOL 463 (Primary)
- Indications Bacterial infections; Bacterial vaginosis
- Focus Therapeutic Use
- Acronyms SUBVert
Most Recent Events
- 24 Mar 2022 Status changed from recruiting to completed.
- 30 Sep 2021 Planned End Date changed from 20 Sep 2021 to 30 Sep 2022.
- 30 Sep 2021 Planned primary completion date changed from 20 Sep 2021 to 30 Sep 2022.